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Abstract Viral infections of the pediatric central nervous
system (CNS) encompass a broad spectrum of both
perinatally and postnatally acquired diseases with poten-
tially devastating effects on the developing brain. In
children, viral infections have been associated with chronic
encephalopathy, encephalitis, demyelinating disease,
tumors, and epilepsy. Older diagnostic techniques of
biopsy, viral culture, electron microscopy, gel-based poly-
merase chain reaction (PCR), and viral titer quantification
are being replaced with more rapid, sensitive, and specific
real-time and microarray-based PCR technologies. Advances
in neuroimaging technologies have provided for earlier
recognition of CNS injury without elucidation of specific
viral etiology. Although the mainstay therapy of many
pediatric neurovirologic diseases, aside from HIV, includes
intravenous acyclovir, much work is being done to develop
novel antiviral immunotherapies aimed at both treating and
preventing pediatric CNS viral disease.
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Introduction
Pediatric neurovirology, although not a formally recognized
subspecialty, is a collaborative effort among many disciplines,
including neonatology, infectious disease, immunology,
neurology, neuropathology, and neuroradiology. Central
nervous system (CNS) viral infections pose a particular
problem in the pediatric population, because both perinatally
and postnatally acquired disease may lead to devastating
consequences for the developing nervous system. For
example, congenital human cytomegalovirus (CMV) infec-
tion, occurring in up to 0.7% of newborns, causes microceph-
aly, cerebral palsy, developmental delay/mental retardation,
and sensorineural hearing and vision loss [1]. Neonatal herpes
simplex virus types 1 and 2 (HSV-1, HSV-2) invade the CNS
in approximately 1500 newborns in the United States yearly,
and may occur via intrauterine (5% of cases), perinatal (85%
of cases), or postnatal (5% of cases) routes, often with
neurologic outcomes similar to those of CMV [2]. In post-
term infants and children, viral encephalitis remains a
considerable diagnostic dilemma for clinicians. Despite
modern diagnostic techniques, a specific viral etiology could
be assigned in only 9% to 30% of cases in three large
multicenter prospective encephalitis studies worldwide [3–5].
CNS infection with human herpesvirus 6 (HHV-6), a
ubiquitous beta herpesvirus that causes roseola infantum, is
increasingly recognized as a potential culprit of both
pediatric encephalitis [6] and epilepsy [7]. The role of
neuroimaging in pediatric and adult CNS infectious disease
is playing an increasingly larger role in diagnosing enceph-
alitis [8]. Through correlation of MRI findings with
laboratory results, it is possible to generate a reasonable
differential diagnosis based on published associations;
however, this approach remains considerably insensitive.
One major limitation in associating viral infections with
disease remains the sensitivity and specificity of the many
molecular diagnostic techniques currently used [9]. Aside
from government-funded agencies such as the California
Encephalitis Project [3], which performs a multitude of
standardized and sophisticated virologic assays, many
clinicians often order a potpourri of diagnostic tests that are
either largely incomplete or excessive, often without diag-
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nostic yield. Neurotropic viruses, both known and emerging,
are being studied in association with a variety of pediatric
diseases, including encephalitis, demyelinating diseases,
tumors, chronic encephalopathy, and epilepsy, to name a
few. The design of more sophisticated diagnostic modalities
and specific viral therapies is at the forefront of pediatric
neurovirology research.
Molecular Diagnostic Testing of Pediatric CNS Viral
Disease
Before the advent of the polymerase chain reaction (PCR)
assay, diagnostic testing in neurovirology was performed
mostly by means of biopsy, viral culture, and antibody titer
analysis. One of the difficulties with viral culture analysis is
that it may take between 1 and 28 days for results, with
poor sensitivity. Viral titer analysis has a similar problem of
cumbersomeness (requiring up to 4 weeks for a convales-
cent phase rise in titers), along with a high seroprevalence
of many neurotropic viruses, limiting the overall specificity
of the assay. Despite these limitations, elevations of some
cerebrospinal fluid (CSF) viral titers (West Nile virus, St.
Louis encephalitis virus, varicella zoster virus [VZV]) are
diagnostic. In the cases of the Flaviviridae and Togaviridae
virus families, acute and convalescent titer elevations
remain diagnostic [10••]. PCR has revolutionized
molecular-based testing in neurovirology and has since
evolved into several varieties. PCR amplification tech-
niques currently used for viral nucleic acid detection in
pediatric CNS disease include conventional PCR, nested
PCR, real-time PCR (RT-PCR), multiplex PCR, and more
recently, loop-mediated isothermal amplification (LAMP)
assay. In patients with presumed encephalitis, nucleic acids
are extracted from CSF with the premise that active viral
infections in the brain will exhibit maximum viral nucleic
acid production, reflected in the CSF [9]. Conventional
qualitative PCR amplifies millions of copies of template
nucleic acid (from 100–200 µL of CSF per PCR reaction)
with just 1 to 10 target copies of DNA/RNA in less than
24 h of processing through the use of DNA-based primers,
a heat-sensitive DNA polymerase, a thermocycler, and a
gel-based detection system. The validity of conventional
PCR was best studied in a large series of biopsy-proven
herpesvirus encephalitis cases, in which HSV PCR was
96% specific and 99% sensitive [11]. Nested PCR uses a
double amplification of template DNA with a set of inner
and outer primers to achieve a sensitivity higher than that of
conventional PCR; however, it also is more time consuming
and more prone to contamination. Recently, a nested PCR
assay was designed to detect aerosolized respiratory
viruses, including influenza A/B, parainfluenza, and human
respiratory syncytial virus, to aid in rapid diagnosis [12].
RT-PCR, the current standard of care in most diagnostic
laboratories, uses a fluorescent probe–based technology
with a fully automated detection system to more accurately
quantitate starting template DNA through real-time analysis
of DNA amplification. RT-PCR is particularly useful in
characterizing viruses of known latency (eg, Epstein-Barr
virus [EBV]) or following trends of viral nucleic acids
after therapy. More recently, LAMP PCR technology was
designed to enhance the detection limits by 10- to 100-fold
without the need for sophisticated equipment [13]. LAMP
involves the design of six primers that bind to eight regions
on the target DNA to form stem–loop structures through
both cyclic and noncyclic amplification steps. The ampli-
fied products can be monitored quantitatively in real time
by either visual turbidity or fluorescence and currently are
used to detect a variety of known and emerging neuro-
pathogens [14]. To circumvent the problem of the relatively
small amounts of pediatric CSF obtained during lumbar
puncture, two multiplex PCR assays for detecting herpes-
viruses in pediatric patients were reported recently [15, 16].
Multiplex PCR uses one reaction tube with a multitude of
virus-specific primers to yield different size products
depending on the target viral sequence. Wada et al. [15]
used unique fluorochrome-linked probes for each of four
herpesvirus primers (HSV-1, HSV-2, HHV-6, and HHV-7),
with a reported sensitivity of 4 copies/reaction. Shi et al.
[16] used a similar multiplex PCR assay for several
herpesviruses (HSV-1, HSV-2, EBV, CMV, and HHV-6)
in pediatric patients, except they conjugated the amplified
PCR products to a fluorochrome and hybridized them onto
a glass chip containing a set of virus-specific DNA
sequences. Compared with standard RT-PCR assays, Shi
et al. [16] reported 91.7% sensitivity and 100% specificity.
These emerging technologies most likely will pave the way
for comprehensive one-step multiplex PCR assays that will
use “viral DNA chips” of the more than 100 viruses known
to be associated with human encephalitis and other CNS
diseases.
Role of Neuroimaging in Pediatric Viral Encephalitis
MRI increasingly is regarded as an important adjuvant tool
in the diagnosis and surveillance of pediatric neurovirologic
disease. Neuroimaging largely has been used retrospectively
in pediatric neurovirology upon laboratory confirmation of
disease. The many published case reports of confirmed viral
encephalitides with associated MRI abnormalities have
served as the initial neuroatlas of pediatric neurovirology,
and MRI remains one of the most sensitive tests for
diagnosing encephalitis in children [8, 17–24]. Aside from
the more typical findings of temporal/inferior frontal
abnormalities seen on MRI in HSV encephalitis or
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subependymal gadolinium enhancement in CMV encepha-
litis, there remains considerable overlap among neurotropic
viruses in both appearance and location on MRI imaging,
as represented in Fig. 1. Japanese encephalitis (JE), a
zoonotic RNA flavivirus endemic to Asia that accounts for
10,000 deaths per year, has been among the most widely
studied in terms of neuroimaging features, largely because
of its high prevalence. Dung et al. [17] found that thalamic
edema was the most frequent abnormality on CT/MRI in 10
of 43 CSF antibody-confirmed pediatric JE cases, with a
negative predictive value of 42.1% and a sensitivity of
100%. However, the specificity of bithalamic edema on
neuroimaging also has been reported in association with
influenza [18] and HHV-6 necrotizing encephalitis [19, 20],
among others. In addition to thalamic abnormalities, West
Nile virus, a flavivirus similar to JE, has been associated in
a small subset of patients with MRI changes in the basal
ganglia, brainstem, cerebellum, periventricular white mat-
ter, mesial temporal lobe, and anterior horns of the spinal
cord similar to those seen in poliomyelitis [21]. Diffusion-
weighted imaging (DWI) and apparent diffusion coefficient
(ADC) mapping may be useful adjuvant MRI sequences in
detecting early signs of viral-mediated vasogenic edema.
Compared with JE patients, HSV encephalitis patients
showed significantly more restricted diffusion and lower
ADC signal in the acute than in the chronic stage of
infection, which may be one of the earliest detectable signs
in HSV encephalitis [22]. DWI frontal lobe abnormalities
also have been reported in patients with HHV-6 encephalitis
[19, 23], in addition to the other signal changes reported in
HHV-6 encephalitis involving the hippocampus, extrahip-
pocampal structures, and rhombencephalon [19, 20, 23,
24], which often lead to chronic necrotization [20]. Single
photon emission CT, magnetic resonance spectroscopy, and
diffusion tensor imaging have been studied far less in
pediatric viral encephalitis and currently have no proven
diagnostic or prognostic value. Advances in molecular
diagnostics, together with improved neuroimaging tech-
niques, will have to work in tandem to help solve the many
challenges clinicians face in establishing a neurovirologic
diagnosis.
Treatment of Pediatric CNS Neurovirologic Disease
Although the current treatment for many pediatric CNS
neurovirologic diseases, exclusive of HIV, is largely
Fig. 1 MRI findings in viral-associated pediatric CNS disease. a
Increased diffusion-weighted imaging signal in the right mesial
temporal lobe (arrowhead) in a patient with polymerase chain reaction
(PCR)-confirmed herpes simplex virus (HSV)-1 encephalitis. b
Periventricular calcifications (arrowhead), diffuse volume loss, and
cerebral dysgenesis in an infant with antibody-positive congenital
cytomegalovirus. c Transverse myelitis (arrowhead) secondary to
HSV-2 in a sexually active teenager with HSV-2–positive cerebrospi-
nal fluid (CSF) PCR and cervical culture. dWest Nile virus confirmed
by CSF serology in a child with acute lower-extremity paresis
revealed by anterior ventral nerve root enhancement on MRI
(arrowhead). e Rapidly progressive encephalopathy with cerebellar
ataxia in a patient with human herpesvirus (HHV)-6 encephalitis and
abnormal cerebellar signal on MRI (arrowhead) confirmed by HHV-6
CSF and biopsy-positive PCR. f Necrotizing encephalopathy in an
infant with influenza B revealed by bithalamic hyperdensities on CT
scan (arrowhead). g Acute encephalopathy in an infant with CSF-
positive respiratory syncytial virus PCR revealed by diffuse cerebellar
abnormalities (arrowhead). h Varicella zoster virus vasculitis in a
patient during acute varicella infection manifested in a right basal
ganglia infarct secondary to right middle cerebellar artery narrowing
(arrowhead)
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supportive, antiviral therapy remains the treatment of
choice for infections involving the Herpesviridae family
of viruses. The overwhelming mechanism of action
commonly evoked by antiviral therapy involves inhibition
of viral DNA polymerase. In the case of acyclovir, an
acyclic deoxyguanosine analogue, three phosphorylations
are required (one by a viral thymidine kinase) before
activation to competitively inhibit viral DNA polymerase
and intercalate into newly synthesized viral DNA to terminate
viral replication. Consequently, antiviral therapy works most
efficiently during early viral replication. Acyclovir therapy
has had tremendous success in improving survival in neonatal
HSV encephalitis, from 50% in the pre-acyclovir era to 14%
with the standard dosage (30 mg/kg per day divided three
times daily) and 4% with the high dosage (60 mg/kg per day
divided three times daily) [25]. Unfortunately, acyclovir
therapy has not had any effect on neurodevelopmental
outcomes in neonates compared with untreated patients
(67% vs 69%) [25]. By comparison, in the postneonatal
period, acyclovir has improved both mortality (70% vs 28%)
and neurologic morbidity (97% vs 62%) at the standard
21-day dosage of 30 mg/kg per day divided three times daily
[2]. Based on these findings, the Infectious Diseases Society
of America recommends treating all patients with suspected
encephalitis with acyclovir until HSV encephalitis has been
ruled out [10••]. In terms of treatment duration, 21 days is
generally recommended, although HSV PCR will remain
positive in a subset of patients, possibly warranting
prolonged therapy [10••]. On the other hand, up to 13% of
pediatric patients have been shown to be HSV PCR negative
early in the disease course [26]; hence, it is recommended
that when there is clinical and/or radiographic suspicion of
HSVencephalitis, repeat HSV PCR be performed within 3 to
7 days (category B evidence) [10••]. If acyclovir is not
available—as was the case in early 2009, when the US Food
and Drug Administration reported a shortage of acyclovir
from the manufacturer—ganciclovir or foscarnet is a
reasonable alternative; however, both agents have substantial
renal and hematologic side effects relative to acyclovir.
Aside from HSV encephalitis treatment with acyclovir,
treatment of the other CNS herpesvirus-associated diseases
carries a lower level of recommendation based on the lack of
available evidence [10••]. In the case of congenital CMV,
ganciclovir at 12 mg/kg per day divided twice daily for
6 weeks has improved hearing outcomes [25]. A subsequent
phase 3 randomized trial in 100 neonates randomly assigned
to receive a 6-week course of ganciclovir therapy (12 mg/kg
per day divided twice daily) or no treatment found
significantly less developmental delays via Denver 2
screening examinations at both 6 months and 12 months in
the treated versus the nontreated infants [27]. CNS VZV
infection may be treated with acyclovir, ganciclovir, or
steroids, whereas CNS EBV treatment remains largely
supportive. For cases of confirmed HHV-6 encephalitis,
ganciclovir or foscarnet may be somewhat efficacious [10••].
Treatments for HHV-7—and HHV-8—associated CNS
disease are much less well studied and do not carry specific
recommendations [10••]. Outside the Herpesviridae family of
CNS diseases, treatment remains largely supportive. Immu-
nomodulatory therapy may play a larger role in the
management of pediatric CNS viral infections in the years
to come. In the case of congenital CMV infection, vaccine
therapy of previously seronegative pregnant females pre-
vented primary maternal infection in 50% of patients
compared with placebo in a phase 2 trial using a recombinant
CMV glycoprotein B vaccine [28•]. Pass et al. [28•]
demonstrated a threefold reduction in congenital CMV
among immunized mothers compared with the placebo
group, although the number of subjects in this study was
relatively small. For prevention of congenital CMV to be
truly successful, it must be introduced as part of the routine
pediatric vaccination schedule after several years of stringent
regulated testing. In cases of CNS influenza or pandemic
influenza A (H1N1), oseltamivir may be used (category C).
With regard to severe cases of nonpolio enterovirus,
intravenous gammaglobulin has shown some efficacy
[10••]. Although pediatric CNS viral therapy currently is
largely supportive, specific antiviral therapies designed to
inhibit viral entry into the CNS (whether vaccine, antibody
mediated, or small molecule) will be required to improve
neurologic morbidity and mortality.
Emerging Pediatric Neurovirologic Diseases
The importance of emerging viral infections in pediatric
neurovirologic disease was highlighted by the recent H1N1
outbreak, which caused significant morbidity and mortality,
especially in the young [29, 30]. Among 343 pediatric
patients diagnosed with H1N1 in California, presenting
features included neurologic symptoms of headache (14%)
and altered mental status (4%) [29]. A second case series
from Texas in four previously healthy children reported
encephalopathy, status epilepticus, and ataxia as presenting
features [30]. All four of these patients had normal CSF
values, and only one patient showed abnormalities on
neuroimaging (cortical T2 hyperintensities on MRI). In
addition to H1N1, there are several other neurotropic
viruses still emerging, as reviewed by Tyler [31•, 32•] in
a recent two-part series. Enterovirus 71, a cause of hand-
foot-and-mouth disease in children, may present with
neurologic sequelae (opsoclonus–myoclonus, cerebellitis,
Guillain-Barré syndrome, transverse myelitis, encephalitis,
aseptic meningitis) in up to a third of patients [31•]. JE is of
concern because of its high prevalence and robust migration
throughout Asia and, more recently, into Australia. JE may
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present with encephalitis, status epilepticus, or focal limb
weakness and has no proven effective treatment, although
candidate vaccines are being developed. Two newer
neurotropic viruses, Nipah and Hendra, have shown
significant neurologic morbidity in affected patients. Nipah
and Hendra viruses, members of the Paramyxoviridae
family, have been associated with brainstem symptoms
and relapsing and/or late-onset encephalitis in up to 8% of
survivors [32]. Whether these neurotropic viruses emerge
through a change in host, through an increase in geographic
range, or by mutational pathogenesis, an epidemiologic
knowledge of geographic viral trends remains the best
chance of early diagnosis, despite the fact that treatment is
largely supportive.
Enlarging Spectrum of Virology-Associated Pediatric
CNS Diseases
Acquired Demyelinating Diseases of Childhood
The acquired demyelinating diseases of childhood include a
diverse category (optic neuritis, clinical isolated syndrome,
acute disseminated encephalomyelitis, multiple sclerosis
[MS], neuromyelitis optica, transverse myelitis) with an
annual incidence of 0.4 per 100,000 [33]. A neurovirologic
etiology has been suggested in many cases, as up to 93% of
patients report an infectious prodrome [33]. In the case of
pediatric MS, the proposed immune-mediated disease
pathophysiology and neuroimaging features that occasion-
ally are similar to those of viral encephalitis have prompted
studies to explore a plausible neurovirologic role in MS.
The best-studied neurotropic virus in association with both
pediatric and adult acquired demyelinating disease is EBV
[34–36]. Alotaibi et al. [34] first reported an association in
2004 whereby 83% of pediatric MS patients (n=30) had
remote serologic evidence of EBV infection compared with
42% of controls (n=143). A follow-up study by Pohl et al.
[35] in 2006 in 147 pediatric MS patients revealed evidence
of remote infection in 98.6% versus 72.1% of controls
(P=0.001). However, neither pediatric controls nor MS
patients showed evidence of acute EBV infection by
serology (antibodies directed against EBV early antigen
or nuclear antigen). Most recently, Pohl et al. [36] reported
intrathecally synthesized EBV antibodies in 26% of
childhood-onset MS (N=43), versus 10% of adult MS
(N=50) and 0% of other pediatric neurologic diseases (N=
32) [36]. Overall, these findings did not support a
causative role of EBV infection in pediatric MS in this
series because EBV PCR was negative in all samples and
30% to 60% of MS patients showed intrathecally
synthesized antibodies to other neurotropic viruses (measles,
rubella, VZV). Although none of the data to date have
showed conclusive evidence for a specific neurotropic virus
in the pathophysiology of pediatric acquired demyelinating
disease, it is possible that future research will reveal a
common overlap among infection-mediated neuroinflamma-
tory disease mechanisms.
Childhood Epilepsy
Among all neurotropic viruses, HHV-6 is one of the most
implicated in the pathophysiology of several childhood
epilepsies, including febrile seizures, status epilepticus,
and mesial temporal lobe epilepsy [37]. HHV-6 exists as
two variants (HHV-6A and HHV-6B) that share greater
than 90% sequence homology [38]. HHV-6 is an attractive
candidate for childhood-onset epilepsy because more than
90% of children show serologic evidence of primary or
latent HHV-6 exposure that occurs at the peak incidence
of febrile seizures [38]. HHV-6B, the more commonly
associated HHV-6 variant in patients with epilepsy, has
been detected in the serum and CSF of pediatric patients
with febrile seizures and febrile status epilepticus and is
the subject of an extensive review by Theodore et al. [37].
Mesial temporal lobe epilepsy, a common cause of
acquired epilepsy, also has been studied with regard to
its association with HHV-6B in both pediatric and adult
patients. Fotheringham et al. [39•] detected HHV-6B by
nested PCR and immunohistochemistry in 8 of 19
pediatric patients with primary mesial temporal lobe
epilepsy who underwent surgical resection. Furthermore,
primary cultured astrocytes obtained after surgery showed
evidence of HHV-6 late antigen by immunofluorescence
microscopy, confirming the presence of active viral
replication as opposed to latent infection [39•]. One
potential mechanism for HHV-6B–mediated epilepsy is
the associated downregulation of glutamate transporter
EAAT-2 after infection of primary cultured astrocytes with
HHV-6 [39•], although there likely are many other
possibilities. Although HHV-6 has been shown to be an
attractive candidate in the pathophysiology of childhood
epilepsy, several other viruses have been detected in
association with febrile seizures [37]. Because most
patients with epilepsy do not undergo surgery, we must rely
on CSF viral detection methods to establish association;
ultimately we will need a viable animal model to truly
establish a causative link between viral infection and
childhood epilepsy.
Primary CNS Malignancies of Childhood
The role of neurotropic viruses in pediatric primary CNS
malignancies currently is an area of controversy in neuro-
virology for several reasons, including an overall lack of
understanding of the immunology of CNS tumors, a lack of
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reproducibility among various researchers regarding viral
detection frequency, and the overall implications of viral
associations for both diagnosis and treatment of CNS
neuro-oncologic disease. Among the many neurotropic
viruses, those of the Polyomavirus and Herpesviridae
families have been studied most in association with
both adult and pediatric primary CNS malignancies. The
Polyomavirus family (JC virus, BK virus, SV40 virus),
particularly JC virus, is of considerable interest in
neuro-oncogenesis, largely based on animal models of JC
virus–induced CNS malignancy [40]. JC virus has a
seroprevalence of 19% to 50%, increasing with age [41].
In adults, JC virus has been detected in several larger
studies by PCR in various tumor subtypes, including
oligodendroglioma, glioma, ependymoma, glioblastoma
multiforme, and medulloblastoma, in approximately one
third to three quarters of cases [40]. JC virus large T
antigen, the putative oncogenic protein, has been detected
in adult tumors roughly half as often by immunohisto-
chemistry than PCR [40]. The role of JC virus in pediatric
CNS tumors has yielded mixed results [42–44]. Krynska et
al. [42] detected JC virus DNA and large T antigen in 11 of
23 medulloblastoma cases, whereas Okamoto et al. [43]
found viral DNA in 5 of 18 ependymoma and 1 of 5
choroid plexus papilloma cases. On the contrary, Vasishta et
al. [44] recently reported that they did not detect JC virus
by immunohistochemistry in their series of 22 medullo-
blastoma patients from India, where seroprevalence is
largely unknown. Among the herpesviruses, CMV has
generated the most controversy in adult neuro-oncology. It
has been detected by PCR, in situ hybridization, and
immunohistochemistry with varied frequencies in adult
glioblastoma multiforme tumors, which prompted clinical
trials using dendritic cell vaccines and antiviral therapies
[45]. Much less is known about the frequencies of CMV in
a large cohort of pediatric tumors; however, unpublished
results from my laboratory suggest CMV DNA is present in
a diversity of tumor types and in normal brain by means of
nested PCR. More recently, HHV-6 variants were detected in
both adult and pediatric primary CNS tumors by both nested
PCR and immunohistochemistry, with a predominance of
viral antigen detected in glial tumors [46, 47]. However,
Neves et al. [48] failed to detect HHV-6 DNA by RT-PCR in
a subset of 35 pilocytic astrocytomas. A potential role for
HHV-6 in pediatric brain tumors is complicated further by
the recent characterization of a chromosomally integrated
HHV-6 variant that accounts for a major mode of transmis-
sion in congenital HHV-6 infection [49•]. Mechanistically,
neurotropic viruses could act via direct cellular transforma-
tion or through oncomodulatory mechanisms [40]. Ulti-
mately, multi-institutional studies and reliable animal model
systems will be necessary to differentiate viral association
from causation in neuro-oncology.
Controversies and Future Directions in Pediatric
Neurovirology
Despite an improved appreciation of the vast number of
neurotropic viruses and their potential roles in pediatric
CNS diseases, there are many controversial areas that likely
will be major areas of focus in the next decade. One area of
contention is how to reliably distinguish viral causation
from association. Part of the difficulty is the inability to
differentiate, by current diagnostic modalities, between lytic
and latent viral infectivity. Because a large proportion of the
population has immunologic evidence of past infection by
serology, it is difficult to prove a causative role for acute
neurotropic viral infection by macromolecular detection
alone. The notion of chronic persistent or latent reactivation
of neurotropic viral infection in CNS disease modification
may be a more plausible hypothesis. Ultimately, we are
limited by the sensitivities of the diagnostic assays in
improving our understanding of neurovirologic disease
phenotypes. For example, it is presumed that viral macro-
molecules detected in CSF represent active infection in the
CNS parenchyma. However, because the amount of DNA
in the CSF often is not quantifiable (eg, in cases of
paucicellular CSF), diagnosis depends on the sensitivity of
the amplification assay being performed. The detection
of intrathecal virus-specific antibodies may have a larger
role in diagnostic neurovirology. A more fundamental
research question that will need to be addressed is, What
is the frequency of neurotropic viruses throughout all ages
of pediatric nondiseased brain, and is there a neuroanatomic
viral tropism? The answers may help us correlate MRI
findings with specific neurovirologic diseases with a goal to
develop newer and more sophisticated neuroimaging
modalities. A final important aspect of neurovirology
research is the design of more specific and efficacious
treatment modalities. Current antiviral therapies are given
parenterally, with little knowledge of CNS penetration and
biodistribution let alone the specific antiviral efficiencies or
appropriate duration of therapy. A multitargeted approach
involving novel viral replication inhibitors, vaccine-based
therapies, and other neuroimmunomodulatory compounds
most likely will be the future of neurovirology treatment
research.
Conclusions
Pediatric neurovirology is a relatively new subspecialty that
spans many disciplines and holds much promise in our
understanding of a multitude of pediatric CNS diseases.
The development of more sensitive, specific, and compre-
hensive diagnostic and treatment modalities is necessary for
the field of pediatric neurovirology to evolve.
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